Diagnostic Imaging Services shares an announcement that the FDA has approved Nerlynx for HER2-positive metastatic breast cancer.Â
Doctors call Nerlynx a HER2 inhibitor or anti-HER2 therapy, a type of targeted therapy that fights HER2-positive breast cancer by blocking the cancer cells’ ability to receive growth signals.Â
https://www.breastcancer.org/research-news/fda-approves-nerlynx-for-her2-pos-mbc







